市場調査レポート

商品コード

1605835

SGLT2阻害薬市場、規模、シェア、動向、産業分析レポート：適応症別、薬剤別、流通チャネル別、地域別 - 市場予測 2025年～2034年

SGLT2 Inhibitors Market Size, Share, Trends, Industry Analysis Report: By Indication (Cardiovascular, Chronic Kidney Disease, Type 2 Diabetes, and Others), Drug, Distribution Channel, and Region - Market Forecast, 2025 - 2034

出版日: 2024年11月01日
発行: Polaris Market Research
ページ情報: 英文 118 Pages
納期: 即日から翌営業日

カスタマイズ可能

価格

PDF (Single User License)

USD 4,250 624,707円

レポートPDFを1名のみがご利用頂けるライセンスです。 PDF内のテキスト等のコピー＆ペーストは可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Multi User License)

USD 5,250 771,697円

レポートPDFを20名様までご利用頂けるライセンスです。 PDF内のテキスト等のコピー＆ペーストは可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Enterprise License)

USD 6,250 918,687円

レポートPDFを同一企業の全世界の方にご利用頂けるライセンスです。ご利用人数に制限はありません。 PDF内のテキスト等のコピー＆ペーストは可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=146.99円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

Polaris Market Research社の最新調査によると、SGLT2阻害薬の世界市場規模は2034年までに327億5,000万米ドルに達する見込みです。このレポートは、現在の市場力学を詳細に洞察し、将来の市場成長に関する分析を提供しています。

ナトリウム・ブドウ糖共輸送担体2（SGLT2）阻害薬市場は、2型糖尿病（T2D）、心不全、慢性腎臓病（CKD）の有病率の増加を背景に、世界の医薬品産業の重要なセグメントとして浮上しています。SGLT2阻害薬は、腎臓から血液中にグルコースを再吸収する役割を担うタンパク質であるナトリウム・ブドウ糖共輸送担体2を阻害することで作用する薬剤クラス別です。

SGLT2阻害薬の市場は、腎臓におけるグルコースの再吸収を阻害することで血糖値を低下させ、2型糖尿病（T2D）の治療における有効性が高まっていることから、大きな成長を遂げています。この成長の背景には、肥満率の上昇、座りがちなライフスタイル、高齢化、不健康な食生活があります。遺伝的素因、都市化、経済格差も北米および世界の糖尿病患者の急増に寄与しています。それによってSGLT2阻害薬の需要が高まっています。

COVID-19の大流行は、糖尿病患者が病状を管理し、重篤な合併症のリスクを軽減するための効果的な治療法を求めたため、SGLT2阻害薬の採用をさらに加速させました。さらに、パンデミックによってオンライン薬局の利用が急増し、これらの薬剤へのアクセスが容易になった。さらに、有利な償還政策、規制当局の承認、製剤における継続的な技術革新が市場をさらに強化しています。

SGLT2阻害薬市場レポートハイライト

2024年、SGLT2阻害薬市場では2型糖尿病領域が最大の売上シェアを占めました。都市化が進むと、運動量の減少、加工食品の消費の増加、ストレスレベルの上昇といったライフスタイルの変化がしばしば見られるようになります。これらの要因が肥満や2型糖尿病の有病率上昇に寄与し、SGLT2阻害薬市場を大きく牽引しています。

オンライン薬局セグメントは、予測期間中に最も高いCAGRで成長しています。オンライン薬局では、オンライン運営に伴う諸経費が削減された結果、競合価格や医薬品の割引が提供されることが多いです。

2024年、北米のSGLT2阻害薬市場は、慢性的なストレスの増加や精神状態の悪化により、最大の市場を占めました。また、北米では糖尿病患者の有病率が増加していることから、SGLT2阻害薬の需要が高まっています。

アジア太平洋地域は、同市場で最も速い成長を占めています。同地域の各国政府は、ヘルスケア・インフラへの投資を増やし、アクセスと質を高める取り組みを行っています。こうした取り組みが医薬品市場とSGLT2阻害薬のような医薬品の採用を支えています。

流通チャネルスナップショット
SGLT2阻害薬市場力学
- 促進要因と機会
  - 世界の高齢化の進行が市場の成長を牽引
  - 新薬承認の増加が市場見通しを牽引
- 抑制要因と課題
  - 高額な医薬品
PESTEL分析
SGLT2阻害薬市場の流通チャネル動向
バリューチェーン分析
COVID-19の影響分析

第5章世界のSGLT2阻害薬市場：適応症別

主な調査結果
イントロダクション
心臓血管
慢性腎臓病（CKD）
2型糖尿病
その他

第6章世界のSGLT2阻害薬市場：薬剤別

主な調査結果
イントロダクション
ファルシーガ（ダパグリフロジン）
インペファ（ソタグリフロジン）
インボカナ（カナグリフロジン）
ジャディアンス（エンパグリフロジン）
Qtern（ダパグリフロジン/サキサグリプチン）
その他のSGLT2阻害薬

第7章世界のSGLT2阻害薬市場：流通チャネル別

主な調査結果
イントロダクション
病院薬局
オンライン薬局
小売薬局

第8章世界のSGLT2阻害薬市場：地域別

主な調査結果
イントロダクション
- SGLT2阻害薬市場評価：地域、2020～2034年
北米
- 北米：適応症別、2020～2034年
- 北米：流通チャネル別、2020年～2034年
- 北米：薬剤別、2020～2034年
- 米国
- カナダ
欧州
- 欧州：適応症別、2020～2034年
- 欧州：流通チャネル別、2020～2034年
- 欧州：薬剤別、2020～2034年
- 英国
- フランス
- ドイツ
- イタリア
- スペイン
- オランダ
- ロシア
- その他欧州
アジア太平洋
- アジア太平洋地域：適応症別、2020年～2034年
- アジア太平洋地域：流通チャネル別、2020～2034年
- アジア太平洋地域：薬剤別、2020年～2034年
- 中国
- インド
- マレーシア
- 日本
- インドネシア
- 韓国
- オーストラリア
- その他アジア太平洋地域
中東・アフリカ
- 中東・アフリカ：適応症別、2020～2034年
- 中東・アフリカ：流通チャネル別、2020～2034年
- 中東・アフリカ：薬剤別、2020～2034年
- サウジアラビア
- アラブ首長国連邦
- イスラエル
- 南アフリカ
- その他中東とアフリカ
ラテンアメリカ
- ラテンアメリカ：適応症別、2020～2034年
- ラテンアメリカ：流通チャネル別、2020～2034年
- ラテンアメリカ：薬物別、2020～2034年
- メキシコ
- ブラジル
- アルゼンチン
- その他ラテンアメリカ

第9章競合情勢

拡大と買収の分析
- 拡大
- 買収
提携/協業/合意/公開

第10章企業プロファイル

AstraZeneca
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Company
Eli Lilly and Company
Glenmark Pharmaceuticals Ltd.
Johnson & Johnson Services, Inc.（Janssen Pharmaceuticals, Inc.）
Lexicon Pharmaceuticals, Inc.
Merck & Co., Inc.
Sanofi
TheracosBio, LLC

図表

List of Tables

Table 1 Global SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
Table 2 Global SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
Table 3 Global SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
Table 4 SGLT2 Inhibitors Market Assessment, By Geography, 2020-2034 (USD Billion)
Table 5 North America: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
Table 6 North America: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
Table 7 North America: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
Table 8 U.S.: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
Table 9 U.S.: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
Table 10 U.S.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
Table 11 Canada: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
Table 12 Canada: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
Table 13 Canada: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
Table 14 Europe: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
Table 15 Europe: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
Table 16 Europe: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
Table 17 UK: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
Table 18 UK: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
Table 19 UK: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
Table 20 France: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
Table 21 France: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
Table 22 France: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
Table 23 Germany: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
Table 24 Germany: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
Table 25 Germany: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
Table 26 Italy: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
Table 27 Italy: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
Table 28 Italy: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
Table 29 Spain: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
Table 30 Spain: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
Table 31 Spain: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
Table 32 Netherlands: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
Table 33 Netherlands: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
Table 34 Netherlands: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
Table 35 Russia: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
Table 36 Russia: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
Table 37 Russia: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
Table 38 Rest of Europe: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
Table 39 Rest of Europe: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
Table 40 Rest of Europe: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
Table 41 Asia Pacific: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
Table 42 Asia Pacific: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
Table 43 Asia Pacific: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
Table 44 China: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
Table 45 China: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
Table 46 China: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
Table 47 India: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
Table 48 India: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
Table 49 India: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
Table 50 Malaysia: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
Table 51 Malaysia: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
Table 52 Malaysia: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
Table 53 Japan: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
Table 54 Japan: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
Table 55 Japan: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
Table 56 Indonesia: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
Table 57 Indonesia: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
Table 58 Indonesia: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
Table 59 South Korea: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
Table 60 South Korea: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
Table 61 South Korea: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
Table 62 Australia: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
Table 63 Australia: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
Table 64 Australia: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
Table 65 Rest of Asia Pacific: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
Table 66 Rest of Asia Pacific: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
Table 67 Rest of Asia Pacific: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
Table 68 Middle East & Africa: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
Table 69 Middle East & Africa: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
Table 70 Middle East & Africa: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
Table 71 Saudi Arabia: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
Table 72 Saudi Arabia: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
Table 73 Saudi Arabia: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
Table 74 UAE: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
Table 75 UAE: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
Table 76 UAE: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
Table 77 Israel: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
Table 78 Israel: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
Table 79 Israel: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
Table 80 South Africa: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
Table 81 South Africa: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
Table 82 South Africa: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
Table 83 Rest of Middle East & Africa: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
Table 84 Rest of Middle East & Africa: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
Table 85 Rest of Middle East & Africa: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
Table 86 Latin America: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
Table 87 Latin America: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
Table 88 Latin America: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
Table 89 Mexico: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
Table 90 Mexico: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
Table 91 Mexico: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
Table 92 Brazil: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
Table 93 Brazil: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
Table 94 Brazil: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
Table 95 Argentina: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
Table 96 Argentina: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
Table 97 Argentina: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
Table 98 Rest of Latin America: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
Table 99 Rest of Latin America: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
Table 100 Rest of Latin America: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)

List of Figures

Figure 1. Global SGLT2 Inhibitors Market, 2020-2034 (USD Billion)
Figure 2. Integrated Ecosystem
Figure 3. Research Methodology: Top-Down & Bottom-Up Approach
Figure 4. Market by Geography
Figure 5. Porter's Five Forces
Figure 6. Market by Indication
Figure 7. Global SGLT2 Inhibitors Market, by Indication, 2024 & 2034 (USD Billion)
Figure 8. Market by Drug
Figure 9. Global SGLT2 Inhibitors Market, by Drug, 2024 & 2034 (USD Billion)
Figure 10. Market by Distribution Channel
Figure 11. Global SGLT2 Inhibitors Market, by Distribution Channel, 2024 & 2034 (USD Billion)

Product Code: PM5187

The global SGLT2 inhibitors market size is expected to reach USD 32.75 billion by 2034, according to a new study by Polaris Market Research. The report "SGLT2 Inhibitors Market Size, Share, Trends, Industry Analysis Report, By Indication (Cardiovascular, Chronic Kidney Disease (CKD), Type 2 Diabetes, and Others), Drug, Distribution Channel, and Region; Segment Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The sodium-glucose cotransporter 2 (SGLT2) inhibitors market has emerged as a significant segment of the global pharmaceutical industry, driven by the increasing prevalence of type 2 diabetes (T2D), heart failure, and chronic kidney diseases (CKD). SGLT2 inhibitors are a class of drugs that work by blocking the sodium-glucose cotransporter 2, a protein responsible for reabsorbing glucose from the kidneys into the bloodstream

The market for SGLT2 inhibitors is experiencing significant growth due to their increasing efficacy in treating type 2 diabetes (T2D) by inhibiting glucose reabsorption in the kidneys and thereby lowering blood sugar levels. This expansion is attributed to the increasing rising obesity rates, sedentary lifestyles, aging populations, and unhealthy diets. Genetic predisposition, urbanization, and economic differences also contribute to the surge in diabetes cases in North America and globally. Thereby boosting demand for SGLT2 inhibitors.

The COVID-19 pandemic has further accelerated the adoption of SGLT2 inhibitors as diabetic patients sought effective treatments to manage their condition and mitigate the risk of severe COVID-19 complications. Additionally, the pandemic has led to a surge in the use of online pharmacies, facilitating accessibility to these medications. Furthermore, favorable reimbursement policies, regulatory approvals, and ongoing innovations in drug formulations further bolster the market.

SGLT2 Inhibitors Market Report Highlights

In 2024, the type 2 diabetes segment accounted for the largest revenue share in the SGLT2 inhibitors market. Urbanization often leads to lifestyle changes characterized by decreased physical activity, increased consumption of processed foods, and higher stress levels. These factors contribute to the rising prevalence of obesity and type 2 diabetes, significantly driving the SGLT2 inhibitors market.

The online pharmacies segment is growing at the highest CAGR during the forecast period. Online pharmacies often offer competitive pricing and discounts on medications as a result of reduced overhead costs associated with online operations.

In 2024, North America SGLT2 inhibitors market accounted for the largest market due to the increasing chronic stress and poor mental. Additionally, the increasing prevalence of diabetes patients in North America has led to a higher demand for SGLT2 inhibitors in the region.

Asia Pacific accounted for the fastest growth in the market. Governments in the region are increasingly investing in healthcare infrastructure and initiatives to enhance access and quality. These efforts support pharmaceutical markets and the adoption of medications like SGLT2 inhibitors.

The global key market players include AstraZeneca; Boehringer Ingelheim International GmbH; Bristol-Myers Squibb Company; Eli Lilly and Company; Glenmark Pharmaceuticals Ltd.; Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals, Inc.); Lexicon Pharmaceuticals, Inc.; Merck & Co., Inc.; Sanofi; and TheracosBio, LLC.

Polaris Market Research has segmented the SGLT2 inhibitors market report based on indication, drug, distribution channel, and region:

By Indication Outlook (Revenue - USD Billion, 2020 - 2034)

Cardiovascular
Chronic Kidney Disease (CKD)
Type 2 Diabetes
Others

By Drug Outlook (Revenue - USD Billion, 2020 - 2034)

Farxiga (Dapagliflozin)
Inpefa (Sotagliflozin)
Invokana (Canagliflozin)
Jardiance (Empagliflozin)
Qtern (Dapagliflozin/Saxagliptin)
Other SGLT2 Inhibitors

By Distribution Channel Outlook (Revenue - USD Billion, 2020 - 2034)

Hospital Pharmacies
Online Pharmacies
Retail Pharmacies

By Regional Outlook (Revenue - USD Billion, 2020 - 2034)

North America
US
Canada
Europe
Germany
UK
France
Italy
Spain
Russia
Netherlands
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Indonesia
Malaysia
Australia
Rest of Asia Pacific
Latin America
Argentina
Brazil
Mexico
Rest of Latin America
Middle East & Africa
UAE
Saudi Arabia
Israel
South Africa
Rest of Middle East & Africa

1. Introduction

1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
1.2. Stakeholders

2. Executive Summary

2.1. Market Highlights

3. Research Methodology

3.1. Overview
- 3.1.1. Data Mining
3.2. Data Sources
- 3.2.1. Primary Sources
- 3.2.2. Secondary Sources

4. Global SGLT2 Inhibitors Market Insights

4.1. SGLT2 Inhibitors Market - Distribution Channel Snapshot
4.2. SGLT2 Inhibitors Market Dynamics
- 4.2.1. Drivers and Opportunities
  - 4.2.1.1. The Global Rise of the Aging Population is Driving Market Growth
  - 4.2.1.2. Rising New Drug Approvals Drive Market Outlook
- 4.2.2. Restraints and Challenges
  - 4.2.2.1. High Cost of Medication
4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
4.4. PESTEL Analysis
4.5. SGLT2 Inhibitors Market Distribution Channel Trends
4.6. Value Chain Analysis
4.7. COVID-19 Impact Analysis

5. Global SGLT2 Inhibitors Market, by Indication

5.1. Key Findings
5.2. Introduction
- 5.2.1. Global SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
5.3. Cardiovascular
- 5.3.1. Global SGLT2 Inhibitors Market, by Cardiovascular, by Region, 2020-2034 (USD Billion)
5.4. Chronic Kidney Disease (CKD)
- 5.4.1. Global SGLT2 Inhibitors Market, by Chronic Kidney Disease (CKD), by Region, 2020-2034 (USD Billion)
5.5. Type 2 Diabetes
- 5.5.1. Global SGLT2 Inhibitors Market, by Type 2 Diabetes, by Region, 2020-2034 (USD Billion)
5.6. Others
- 5.6.1. Global SGLT2 Inhibitors Market, by Others, by Region, 2020-2034 (USD Billion)

6. Global SGLT2 Inhibitors Market, by Drug

6.1. Key Findings
6.2. Introduction
- 6.2.1. Global SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
6.3. Farxiga (Dapagliflozin)
- 6.3.1. Global SGLT2 Inhibitors Market, by Farxiga (Dapagliflozin), by Region, 2020-2034 (USD Billion)
6.4. Inpefa (Sotagliflozin)
- 6.4.1. Global SGLT2 Inhibitors Market, by Inpefa (Sotagliflozin), by Region, 2020-2034 (USD Billion)
6.5.Invokana (Canagliflozin)
- 6.5.1. Global SGLT2 Inhibitors Market, by Invokana (Canagliflozin), by Region, 2020-2034 (USD Billion)
6.6. Jardiance (Empagliflozin)
- 6.6.1. Global SGLT2 Inhibitors Market, by Jardiance (Empagliflozin), by Region, 2020-2034 (USD Billion)
6.5. Qtern (Dapagliflozin/Saxagliptin)
- 6.5.1. Global SGLT2 Inhibitors Market, by Qtern (Dapagliflozin/Saxagliptin), by Region, 2020-2034 (USD Billion)
6.5. Other SGLT2 Inhibitors
- 6.5.1. Global SGLT2 Inhibitors Market, by Other SGLT2 Inhibitors, by Region, 2020-2034 (USD Billion)

7. Global SGLT2 Inhibitors Market, by Distribution Channel

7.1. Key Findings
7.2. Introduction
- 7.2.1. Global SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
7.3. Hospital Pharmacies
- 7.3.1. Global SGLT2 Inhibitors Market, by Hospital Pharmacies, By Region, 2020-2034 (USD Billion)
7.4. Online Pharmacies
- 7.4.1. Global SGLT2 Inhibitors Market, by Online Pharmacies, By Region, 2020-2034 (USD Billion)
7.5. Retail Pharmacies
- 7.5.1. Global SGLT2 Inhibitors Market, by Retail Pharmacies, By Region, 2020-2034 (USD Billion)

8. Global SGLT2 Inhibitors Market, by Geography

8.1. Key findings
8.2. Introduction
- 8.2.1. SGLT2 Inhibitors Market Assessment, By Geography, 2020-2034 (USD Billion)
8.3. SGLT2 Inhibitors Market - North America
- 8.3.1. North America: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
- 8.3.2. North America: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.3.3. North America: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
- 8.3.4. SGLT2 Inhibitors Market - U.S.
  - 8.3.4.1. U.S.: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
  - 8.3.4.2. U.S.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
  - 8.3.4.3. U.S.: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
- 8.3.5. SGLT2 Inhibitors Market - Canada
  - 8.3.5.1. Canada: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
  - 8.3.5.2. Canada.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
  - 8.3.5.3. Canada: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
8.4. SGLT2 Inhibitors Market - Europe
- 8.4.1. Europe: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
- 8.4.2. Europe.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.4.3. Europe: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
- 8.4.4. SGLT2 Inhibitors Market - UK
  - 8.4.4.1. UK: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
  - 8.4.4.2. UK.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
  - 8.4.4.3. UK: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
- 8.4.5. SGLT2 Inhibitors Market - France
  - 8.4.5.1. France: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
  - 8.4.5.2. France.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
  - 8.4.5.3. France: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
- 8.4.6. SGLT2 Inhibitors Market - Germany
  - 8.4.6.1. Germany: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
  - 8.4.6.2. Germany.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
  - 8.4.6.3. Germany: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
- 8.4.7. SGLT2 Inhibitors Market - Italy
  - 8.4.7.1. Italy: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
  - 8.4.7.2. Italy.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
  - 8.4.7.3. Italy: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
- 8.4.8. SGLT2 Inhibitors Market - Spain
  - 8.4.8.1. Spain: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
  - 8.4.8.2. Spain.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
  - 8.4.8.3. Spain: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
- 8.4.9. SGLT2 Inhibitors Market - Netherlands
  - 8.4.9.1. Netherlands: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
  - 8.4.9.2. Netherlands.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
  - 8.4.9.3. Netherlands: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
- 8.4.10. SGLT2 Inhibitors Market - Russia
  - 8.4.10.1. Russia: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
  - 8.4.10.2. Russia.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
  - 8.4.10.3. Russia: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
- 8.4.11. SGLT2 Inhibitors Market - Rest of Europe
  - 8.4.11.1. Rest of Europe: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
  - 8.4.11.2. Rest of Europe.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
  - 8.4.11.3. Rest of Europe: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
8.5. SGLT2 Inhibitors Market - Asia Pacific
- 8.5.1. Asia Pacific: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
- 8.5.2. Asia Pacific.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.5.3. Asia Pacific: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
- 8.5.4. SGLT2 Inhibitors Market - China
  - 8.5.4.1. China: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
  - 8.5.4.2. China.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
  - 8.5.4.3. China: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
- 8.5.5. SGLT2 Inhibitors Market - India
  - 8.5.5.1. India: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
  - 8.5.5.2. India.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
  - 8.5.5.3. India: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
- 8.5.6. SGLT2 Inhibitors Market - Malaysia
  - 8.5.6.1. Malaysia: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
  - 8.5.6.2. Malaysia.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
  - 8.5.6.3. Malaysia: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
- 8.5.7. SGLT2 Inhibitors Market - Japan
  - 8.5.7.1. Japan: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
  - 8.5.7.2. Japan.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
  - 8.5.7.3. Japan: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
- 8.5.8. SGLT2 Inhibitors Market - Indonesia
  - 8.5.8.1. Indonesia: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
  - 8.5.8.2. Indonesia.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
  - 8.5.8.3. Indonesia: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
- 8.5.9. SGLT2 Inhibitors Market - South Korea
  - 8.5.9.1. South Korea: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
  - 8.5.9.2. South Korea: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
  - 8.5.9.3. South Korea: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
- 8.5.10. SGLT2 Inhibitors Market - Australia
  - 8.5.10.1. Australia: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
  - 8.5.10.2. Australia: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
  - 8.5.10.3. Australia: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
- 8.5.11. SGLT2 Inhibitors Market - Rest of Asia Pacific
  - 8.5.11.1. Rest of Asia Pacific: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
  - 8.5.11.2. Rest of Asia Pacific: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
  - 8.5.11.3. Rest of Asia Pacific: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
8.6. SGLT2 Inhibitors Market - Middle East & Africa
- 8.6.1. Middle East & Africa: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
- 8.6.2. Middle East & Africa.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.6.3. Middle East & Africa: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
- 8.6.4. SGLT2 Inhibitors Market - Saudi Arabia
  - 8.6.4.1. Saudi Arabia: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
  - 8.6.4.2. Saudi Arabia.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
  - 8.6.4.3. Saudi Arabia: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
- 8.6.5. SGLT2 Inhibitors Market - UAE
  - 8.6.5.1. UAE: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
  - 8.6.5.2. UAE.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
  - 8.6.5.3. UAE: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
- 8.6.6. SGLT2 Inhibitors Market - Israel
  - 8.6.6.1. Israel: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
  - 8.6.6.2. Israel.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
  - 8.6.6.3. Israel: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
- 8.6.7. SGLT2 Inhibitors Market - South Africa
  - 8.6.7.1. South Africa: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
  - 8.6.7.2. South Africa.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
  - 8.6.7.3. South Africa: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
- 8.6.8. SGLT2 Inhibitors Market - Rest of Middle East & Africa
  - 8.6.8.1. Rest of Middle East & Africa: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
  - 8.6.8.2. Rest of Middle East & Africa: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
  - 8.6.8.3. Rest of Middle East & Africa: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
8.7. SGLT2 Inhibitors Market - Latin America
- 8.7.1. Latin America: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
- 8.7.2. Latin America.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
- 8.7.3. Latin America: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
- 8.7.4. SGLT2 Inhibitors Market - Mexico
  - 8.7.4.1. Mexico: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
  - 8.7.4.2. Mexico.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
  - 8.7.4.3. Mexico: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
- 8.7.5. SGLT2 Inhibitors Market - Brazil
  - 8.7.5.1. Brazil: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
  - 8.7.5.2. Brazil.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
  - 8.7.5.3. Brazil: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
- 8.7.6. SGLT2 Inhibitors Market - Argentina
  - 8.7.6.1. Argentina: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
  - 8.7.6.2. Argentina.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
  - 8.7.6.3. Argentina: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)
- 8.7.7. SGLT2 Inhibitors Market - Rest of Latin America
  - 8.7.7.1. Rest of Latin America: SGLT2 Inhibitors Market, by Indication, 2020-2034 (USD Billion)
  - 8.7.7.2. Rest of Latin America.: SGLT2 Inhibitors Market, by Distribution Channel, 2020-2034 (USD Billion)
  - 8.7.7.3. Rest of Latin America: SGLT2 Inhibitors Market, by Drug, 2020-2034 (USD Billion)

9. Competitive Landscape

9.1. Expansion and Acquisition Analysis
- 9.1.1. Expansion
- 9.1.2. Acquisitions
9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

10.1. AstraZeneca
- 10.1.1. Company Overview
- 10.1.2. Financial Performance
- 10.1.3. Product Benchmarking
- 10.1.4. Recent Development
10.2. Boehringer Ingelheim International GmbH
- 10.2.1. Company Overview
- 10.2.2. Financial Performance
- 10.2.3. Product Benchmarking
- 10.2.4. Recent Development
10.3. Bristol-Myers Squibb Company
- 10.3.1. Company Overview
- 10.3.2. Financial Performance
- 10.3.3. Product Benchmarking
- 10.3.4. Recent Development
10.4. Eli Lilly and Company
- 10.4.1. Company Overview
- 10.4.2. Financial Performance
- 10.4.3. Product Benchmarking
- 10.4.4. Recent Development
10.5. Glenmark Pharmaceuticals Ltd.
- 10.5.1. Company Overview
- 10.5.2. Financial Performance
- 10.5.3. Product Benchmarking
- 10.5.4. Recent Development
10.6. Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals, Inc.)
- 10.6.1. Company Overview
- 10.6.2. Financial Performance
- 10.6.3. Product Benchmarking
- 10.6.4. Recent Development
10.7. Lexicon Pharmaceuticals, Inc.
- 10.7.1. Company Overview
- 10.7.2. Financial Performance
- 10.7.3. Product Benchmarking
- 10.7.4. Recent Development
10.8. Merck & Co., Inc.
- 10.8.1. Company Overview
- 10.8.2. Financial Performance
- 10.8.3. Product Benchmarking
- 10.8.4. Recent Development
10.9. Sanofi
- 10.9.1. Company Overview
- 10.9.2. Financial Performance
- 10.9.3. Product Benchmarking
- 10.9.4. Recent Development
10.10. TheracosBio, LLC
- 10.10.1. Company Overview
- 10.10.2. Financial Performance
- 10.10.3. Product Benchmarking
- 10.10.4. Recent Development

SGLT2阻害薬市場、規模、シェア、動向、産業分析レポート：適応症別、薬剤別、流通チャネル別、地域別 - 市場予測 2025年～2034年

SGLT2 Inhibitors Market Size, Share, Trends, Industry Analysis Report: By Indication (Cardiovascular, Chronic Kidney Disease, Type 2 Diabetes, and Others), Drug, Distribution Channel, and Region - Market Forecast, 2025 - 2034

SGLT2阻害薬市場レポートハイライト

目次

第1章イントロダクション

第2章エグゼクティブサマリー

第3章調査手法

第4章世界のSGLT2阻害薬市場の洞察

第5章世界のSGLT2阻害薬市場：適応症別

第6章世界のSGLT2阻害薬市場：薬剤別

第7章世界のSGLT2阻害薬市場：流通チャネル別

第8章世界のSGLT2阻害薬市場：地域別

第9章競合情勢

第10章企業プロファイル

List of Tables

List of Figures

SGLT2 Inhibitors Market Report Highlights

By Indication Outlook (Revenue - USD Billion, 2020 - 2034)

By Drug Outlook (Revenue - USD Billion, 2020 - 2034)

By Distribution Channel Outlook (Revenue - USD Billion, 2020 - 2034)

By Regional Outlook (Revenue - USD Billion, 2020 - 2034)

Table of Contents

1. Introduction

2. Executive Summary

3. Research Methodology

4. Global SGLT2 Inhibitors Market Insights

5. Global SGLT2 Inhibitors Market, by Indication

6. Global SGLT2 Inhibitors Market, by Drug

7. Global SGLT2 Inhibitors Market, by Distribution Channel

8. Global SGLT2 Inhibitors Market, by Geography

9. Competitive Landscape

10. Company Profiles

SGLT2阻害薬市場、規模、シェア、動向、産業分析レポート：適応症別、薬剤別、流通チャネル別、地域別 - 市場予測 2025年～2034年

SGLT2 Inhibitors Market Size, Share, Trends, Industry Analysis Report: By Indication (Cardiovascular, Chronic Kidney Disease, Type 2 Diabetes, and Others), Drug, Distribution Channel, and Region - Market Forecast, 2025 - 2034

SGLT2阻害薬市場レポートハイライト

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 調査手法

第4章 世界のSGLT2阻害薬市場の洞察

第5章 世界のSGLT2阻害薬市場：適応症別

第6章 世界のSGLT2阻害薬市場：薬剤別

第7章 世界のSGLT2阻害薬市場：流通チャネル別

第8章 世界のSGLT2阻害薬市場：地域別

第9章 競合情勢

第10章 企業プロファイル

List of Tables

List of Figures

SGLT2 Inhibitors Market Report Highlights

By Indication Outlook (Revenue - USD Billion, 2020 - 2034)

By Drug Outlook (Revenue - USD Billion, 2020 - 2034)

By Distribution Channel Outlook (Revenue - USD Billion, 2020 - 2034)

By Regional Outlook (Revenue - USD Billion, 2020 - 2034)

Table of Contents

1. Introduction

2. Executive Summary

3. Research Methodology

4. Global SGLT2 Inhibitors Market Insights

5. Global SGLT2 Inhibitors Market, by Indication

6. Global SGLT2 Inhibitors Market, by Drug

7. Global SGLT2 Inhibitors Market, by Distribution Channel

8. Global SGLT2 Inhibitors Market, by Geography

9. Competitive Landscape

10. Company Profiles

第1章イントロダクション

第2章エグゼクティブサマリー

第3章調査手法

第4章世界のSGLT2阻害薬市場の洞察

第5章世界のSGLT2阻害薬市場：適応症別

第6章世界のSGLT2阻害薬市場：薬剤別

第7章世界のSGLT2阻害薬市場：流通チャネル別

第8章世界のSGLT2阻害薬市場：地域別

第9章競合情勢

第10章企業プロファイル